Thursday 16 October, 2025
Objectives: We previously developed an integrated population PK model of posaconazole oral suspension (SUS), delayed-release tablet (DR-tablet), and intravenous injection (IV),…
Read moreAbstracts
Time-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer’s Disease
Thursday 16 October, 2025
Objectives: Hydromethylthionine mesylate (HMTM) is an orally administered tau aggregation inhibitor (TAI), that also disaggregates pathological tau oligomers and filaments….
Read moreUnravelling the effects of acute inflammation on pharmacokinetics: a model-based analysis focusing on renal excretion and CYP3A4-mediated metabolism
Thursday 16 October, 2025
Objectives: Acute inflammation, caused by infections or sepsis, can impact pharmacokinetics (PK). Here, we used a model-based analysis to evaluate…
Read moreModeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide
Thursday 16 October, 2025
Objectives: Sepsis is a life-threatening condition that arises when the body’s response to infection causes injury to its own tissues…
Read morePharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is the most common cause of death in HIV-infected individuals. Isoniazid in combination with rifampicin, pyrazinamide and…
Read moreModel-based characterization of drug-drug interaction between isoniazid and rifampicin
Thursday 16 October, 2025
Objectives: Rifampicin and isoniazid are the backbone of the current first-line antitubercular therapy. Isoniazid is primarily eliminated by formation of…
Read moreA novel hemodynamic systems model to quantify pharmacodynamic effects on heart rate and contractility
Thursday 16 October, 2025
Objectives: Cardiovascular safety issues are a main causes associated with attrition during drug development. Most attention has been attributed to…
Read moreA translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables
Thursday 16 October, 2025
Objectives: Cardiovascular safety issues are among the major causes of safety-related attrition in drug development.1 Early prediction and quantification of…
Read moreHemodynamic systems model to characterize cardiovascular drug effects
Thursday 16 October, 2025
Objectives: The cardiovascular hemodynamic system is complex and highly regulated. Drugs can affect hemodynamic function through different modes of action….
Read moreThe dynamics of pharmacological effects aimed at gut wall: A framework for a nested-target-within-enterocyte (NTWE) model that accounts for turnover of target and cell
Thursday 16 October, 2025
Introduction: The gastrointestinal (GI) tract has been the focus of several potential therapeutic target linked to metabolic diseases, cancer, inflammatory…
Read more